LifeMD Announces Exclusive Collaboration to Launch Direct-to-Patient Self-Pay Program for XYOSTED® (testosterone enanthate) Injection
LifeMD entered an exclusive co-marketing collaboration with Halozyme’s Antares Pharma to launch a direct-to-patient self-pay program for XYOSTED, the only FDA-approved once-weekly subcutaneous testosterone auto-injector. The program is set to launch in July 2026 across 37 states, offering the treatment at a transparent all-inclusive price of approximately $249 per month that covers both medication and clinical care.
Key figures
- Launch date
- July 2026
- Launch states
- 37
- Program price monthly
- $249
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.